In summary, OVV therapy induces functional impairment in DCs and exhaustion of CD8+ T cells, while anti-TIM-3 intervention effectively reprograms DCs toward immunostimulatory phenotypes, thereby augmenting T cells-mediated tumor control. The gene discussed is CD8A; the disease is neoplasm.